ETF Holdings Breakdown of RGNX

Stock NameRegenxbio Inc
TickerRGNX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75901B1070
LEI549300EOES47LATSET33

News associated with RGNX

Tower Research Capital LLC TRC Acquires 10,714 Shares of REGENXBIO Inc. (NASDAQ:RGNX)
Tower Research Capital LLC TRC increased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 442.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,138 shares of the biotechnology company’s stock after acquiring an additional 10,714 shares during the […] - 2025-05-09 08:23:02
Norges Bank Makes New $3.47 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)
Norges Bank purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 449,400 shares of the biotechnology company’s stock, valued at approximately $3,474,000. Several other institutional investors and hedge funds also recently […] - 2025-04-11 08:13:01
Mitsubishi UFJ Asset Management Co. Ltd. Has $198,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX)
Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 48.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 25,430 shares of the biotechnology company’s stock after buying an additional 8,267 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in […] - 2025-04-04 08:12:56
EntryPoint Capital LLC Invests $97,000 in REGENXBIO Inc. (NASDAQ:RGNX)
EntryPoint Capital LLC acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 12,538 shares of the biotechnology company’s stock, valued at approximately $97,000. Other large investors have also bought and sold shares […] - 2025-03-31 08:24:54
REGENXBIO Inc. (NASDAQ:RGNX) Receives $33.88 Average Price Target from Brokerages
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price […] - 2025-03-25 05:36:46
AlphaQuest LLC Trims Stake in REGENXBIO Inc. (NASDAQ:RGNX)
AlphaQuest LLC decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 66.9% during the fourth quarter, Holdings Channel reports. The fund owned 7,959 shares of the biotechnology company’s stock after selling 16,113 shares during the period. AlphaQuest LLC’s holdings in REGENXBIO were worth $62,000 as of its most recent SEC filing. […] - 2025-03-20 08:13:10
HC Wainwright Issues Pessimistic Forecast for REGENXBIO (NASDAQ:RGNX) Stock Price
REGENXBIO (NASDAQ:RGNX – Free Report) had its price target cut by HC Wainwright from $36.00 to $34.00 in a research report sent to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. A number of other equities analysts also recently weighed in on RGNX. The Goldman Sachs Group […] - 2025-03-18 05:54:45
REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by New York State Common Retirement Fund
New York State Common Retirement Fund decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 17.4% in the fourth quarter, HoldingsChannel reports. The firm owned 13,746 shares of the biotechnology company’s stock after selling 2,900 shares during the quarter. New York State Common Retirement Fund’s holdings in REGENXBIO were worth $106,000 […] - 2025-03-06 10:19:25
Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Target Price at $33.45
Shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target […] - 2025-02-28 06:43:06
REGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by StockNews.com
REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REGENXBIO […] - 2025-02-27 06:15:04
StockNews.com Downgrades REGENXBIO (NASDAQ:RGNX) to Sell
REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday. Several other research firms have also issued reports on RGNX. The Goldman Sachs Group lowered shares of REGENXBIO from a “buy” rating to a “neutral” […] - 2025-02-17 06:39:03
The Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to Neutral
REGENXBIO (NASDAQ:RGNX – Get Free Report) was downgraded by analysts at The Goldman Sachs Group from a “buy” rating to a “neutral” rating in a report issued on Tuesday, MarketBeat reports. They presently have a $14.00 price objective on the biotechnology company’s stock, down from their prior price objective of $38.00. The Goldman Sachs Group’s […] - 2025-02-13 08:46:49
Raymond James Initiates Coverage on REGENXBIO (NASDAQ:RGNX)
Raymond James assumed coverage on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research note issued to investors on Friday morning. The firm issued an outperform rating and a $27.00 price target on the biotechnology company’s stock. A number of other analysts have also commented on the company. StockNews.com lowered REGENXBIO from a “hold” […] - 2025-02-10 16:57:04

RGNX institutional holdings

The following institutional investment holdings of RGNX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-02-27 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 38,589USD 254,687 -1.1%
2025-02-27 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 4,612USD 30,439 -1.1%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 49,663USD 355,090 -1.3%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 24,669USD 176,383 -1.3%
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 24,669USD 176,383 -1.3%
Total =142,202 USD 992,982
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.